At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
XFOR X4 Pharmaceuticals Inc
Market Closed 06-26 16:00:00 EDT
4.02
+0.03
+0.75%
盘后4.04
+0.02+0.50%
18:46 EDT
High4.24Low3.98Vol10.48M
Open3.98D1 Closing3.99Amplitude6.39%
Mkt Cap379.17MTradable Cap273.16MTotal Shares94.32M
T/O42.18MT/O Rate15.42%Tradable Shares67.95M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

X4 Pharmaceuticals Initiated at Outperform by Leerink Partners
Dow Jones  ·  06-02
X4 Pharmaceuticals Initiated at Outperform by Leerink Partners
X4 Pharmaceuticals initiated with an Outperform at Leerink
TIPRANKS  ·  06-02
X4 Pharmaceuticals initiated with an Outperform at Leerink
X4 Pharmaceuticals Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $12
THOMSON REUTERS  ·  06-02
X4 Pharmaceuticals Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $12
U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik
Reuters  ·  06-02
U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik
BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule
Reuters  ·  06-02
BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule
X4 Pharmaceuticals grants 160,000 inducement stock options priced at $4.31 per share
Reuters  ·  06-02
X4 Pharmaceuticals grants 160,000 inducement stock options priced at $4.31 per share
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  06-02
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
X4 Pharma to present at Jefferies Global Healthcare Conference
Reuters  ·  05-27
X4 Pharma to present at Jefferies Global Healthcare Conference
X4 Pharmaceuticals corrects director nominee name in amended 8-K filing
Reuters  ·  05-14
X4 Pharmaceuticals corrects director nominee name in amended 8-K filing
X4 Pharmaceuticals shareholders approved amended 2017 equity incentive plan share increase
Reuters  ·  05-13
X4 Pharmaceuticals shareholders approved amended 2017 equity incentive plan share increase
BRIEF-X4 Pharmaceuticals Inc - May Offer Up To $300 Million Of Common Stock, Preferred Stock, Debt Securities, Warrants, And/Or Units - SEC Filing
Reuters  ·  05-07
BRIEF-X4 Pharmaceuticals Inc - May Offer Up To $300 Million Of Common Stock, Preferred Stock, Debt Securities, Warrants, And/Or Units - SEC Filing
X4 Pharmaceuticals Inc - May Offer up to $300 Mln of Common Stock, Preferred Stock, Debt Securities, Warrants, and/or Units - SEC Filing
THOMSON REUTERS  ·  05-07
X4 Pharmaceuticals Inc - May Offer up to $300 Mln of Common Stock, Preferred Stock, Debt Securities, Warrants, and/or Units - SEC Filing
X4 Pharmaceuticals net loss widens to $20.2 million in Q1 FY26; revenue drops to $2.7 million
Reuters  ·  05-06
X4 Pharmaceuticals net loss widens to $20.2 million in Q1 FY26; revenue drops to $2.7 million
BRIEF-X4 Pharmaceuticals Q1 EPS USD -0.16
Reuters  ·  05-06
BRIEF-X4 Pharmaceuticals Q1 EPS USD -0.16
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
THOMSON REUTERS  ·  05-06
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
X4 Pharmaceuticals Q1 Operating Expenses USD 23.014 Million
THOMSON REUTERS  ·  05-06
X4 Pharmaceuticals Q1 Operating Expenses USD 23.014 Million
X4 says EU approves Xolremdi for WHIM syndrome treatment
Reuters  ·  04-29
X4 says EU approves Xolremdi for WHIM syndrome treatment
X4 Pharmaceuticals Announces European Commission Approval of Xolremdi® (Mavorixafor), the First and Only Authorized Treatment for Patients With Whim Syndrome in the European Union
THOMSON REUTERS  ·  04-29
X4 Pharmaceuticals Announces European Commission Approval of Xolremdi® (Mavorixafor), the First and Only Authorized Treatment for Patients With Whim Syndrome in the European Union
X4 Pharmaceuticals Inc expected to post a loss of 20 cents a share - Earnings Preview
Reuters  ·  04-27
X4 Pharmaceuticals Inc expected to post a loss of 20 cents a share - Earnings Preview
BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Reuters  ·  04-02
BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Introduction

Company Name.
X4 Pharmaceuticals Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
Issue price:
--